Audentes Therapeutics, Inc. (BOLD) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO, CA 94108 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 378,638,000 | 369,504,000 | 414,307,000 | 280,686,000 | 314,434,000 | 326,128,000 | |||
| Cash and cash equivalent | 98,995,000 | 133,160,000 | 144,349,000 | 104,339,000 | 214,495,000 | 230,864,000 | |||
| Short-term investments | 279,643,000 | 236,344,000 | 269,958,000 | 176,347,000 | 99,939,000 | 95,264,000 | |||
| Restricted cash and investments | 90,000 | ||||||||
| Other undisclosed current assets | 14,203,000 | 3,651,000 | 5,465,000 | 4,642,000 | 4,997,000 | 3,155,000 | |||
| Total current assets: | 392,841,000 | 373,155,000 | 419,772,000 | 285,328,000 | 319,431,000 | 329,373,000 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 25,577,000 | ✕ | ✕ | ✕ | ✕ | ||||
| Property, plant and equipment | 37,467,000 | 34,731,000 | 32,099,000 | 30,653,000 | 29,340,000 | 26,436,000 | |||
| Long-term investments and receivables | 5,517,000 | 1,252,000 | |||||||
| Long-term investments | 5,517,000 | 1,252,000 | |||||||
| Intangible assets, net (including goodwill) | 11,631,000 | 11,631,000 | 11,631,000 | 11,631,000 | 11,631,000 | 11,631,000 | |||
| Goodwill | 3,631,000 | 3,631,000 | 3,631,000 | 3,631,000 | 3,631,000 | 3,631,000 | |||
| Intangible assets, net (excluding goodwill) | 8,000,000 | 8,000,000 | 8,000,000 | 8,000,000 | 8,000,000 | 8,000,000 | |||
| Restricted cash and investments | 3,748,000 | 3,748,000 | 3,748,000 | 3,604,000 | 3,604,000 | 3,604,000 | |||
| Other noncurrent assets | 6,850,000 | 5,305,000 | 5,305,000 | 5,305,000 | 2,045,000 | 2,045,000 | |||
| Other undisclosed noncurrent assets | 21,089,000 | ||||||||
| Total noncurrent assets: | 85,273,000 | 82,021,000 | 52,783,000 | 52,445,000 | 46,620,000 | 43,716,000 | |||
| TOTAL ASSETS: | 478,114,000 | 455,176,000 | 472,555,000 | 337,773,000 | 366,051,000 | 373,089,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 24,078,000 | 23,331,000 | 21,051,000 | 18,804,000 | 16,343,000 | 13,350,000 | |||
| Accounts payable | 7,181,000 | 11,811,000 | 8,123,000 | 3,224,000 | 4,959,000 | 5,301,000 | |||
| Accrued liabilities | 16,897,000 | 11,520,000 | 12,928,000 | 15,580,000 | 11,384,000 | 8,049,000 | |||
| Debt | 3,247,000 | ||||||||
| Deferred rent credit | 456,000 | 442,000 | 424,000 | ||||||
| Business combination, contingent consideration, liability | 2,345,000 | 2,359,000 | |||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 410,000 | ||
| Other undisclosed current liabilities | 2,773,000 | ||||||||
| Total current liabilities: | 27,325,000 | 26,104,000 | 23,852,000 | 19,246,000 | 16,767,000 | 16,119,000 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 27,444,000 | ||||||||
| Liabilities, other than long-term debt | 3,643,000 | 2,544,000 | 5,949,000 | 7,920,000 | 8,265,000 | 4,468,000 | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 2,694,000 | ||
| Deferred rent credit | 4,720,000 | 4,078,000 | 4,182,000 | ||||||
| Asset retirement obligations | 226,000 | 221,000 | 215,000 | 512,000 | 769,000 | 760,000 | |||
| Deferred tax liabilities, net | ✕ | ✕ | ✕ | 1,014,000 | 1,014,000 | 1,014,000 | 1,014,000 | ||
| Deferred income tax liabilities | 1,014,000 | ✕ | ✕ | ✕ | ✕ | ||||
| Operating lease, liability | 27,444,000 | ✕ | ✕ | ✕ | ✕ | ||||
| Business combination, contingent consideration, liability | 2,403,000 | 2,323,000 | 2,316,000 | 2,300,000 | |||||
| Other undisclosed noncurrent liabilities | 24,533,000 | 52,000 | 55,000 | 60,000 | |||||
| Total noncurrent liabilities: | 31,087,000 | 27,077,000 | 5,949,000 | 7,972,000 | 8,320,000 | 4,528,000 | |||
| Total liabilities: | 58,412,000 | 53,181,000 | 29,801,000 | 27,218,000 | 25,087,000 | 20,647,000 | |||
| Equity | |||||||||
| Equity, attributable to parent | 419,702,000 | 401,995,000 | 442,754,000 | 310,555,000 | 340,964,000 | 352,442,000 | |||
| Additional paid in capital | 833,101,000 | 770,789,000 | 762,284,000 | 594,480,000 | 588,594,000 | 568,756,000 | |||
| Accumulated other comprehensive income (loss) | 226,000 | 67,000 | (60,000) | (47,000) | (43,000) | (94,000) | |||
| Accumulated deficit | (413,625,000) | (368,861,000) | (319,470,000) | (283,878,000) | (247,587,000) | (216,220,000) | |||
| Total equity: | 419,702,000 | 401,995,000 | 442,754,000 | 310,555,000 | 340,964,000 | 352,442,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 478,114,000 | 455,176,000 | 472,555,000 | 337,773,000 | 366,051,000 | 373,089,000 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (47,077,000) | (51,830,000) | (37,598,000) | (37,735,000) | (32,629,000) | (26,410,000) | ||
| Operating loss: | (47,077,000) | (51,830,000) | (37,598,000) | (37,735,000) | (32,629,000) | (26,410,000) | ||
| Nonoperating income | 2,313,000 | 2,439,000 | 2,006,000 | 1,444,000 | 1,262,000 | 839,000 | ||
| Investment income, nonoperating | 2,353,000 | 2,472,000 | 2,368,000 | 1,509,000 | 1,294,000 | 859,000 | ||
| Other nonoperating expense | (40,000) | (33,000) | (362,000) | (65,000) | (32,000) | (20,000) | ||
| Loss from continuing operations: | (44,764,000) | (49,391,000) | (35,592,000) | (36,291,000) | (31,367,000) | (25,571,000) | ||
| Loss before gain (loss) on sale of properties: | (44,764,000) | (49,391,000) | (35,592,000) | (36,291,000) | (31,367,000) | (25,571,000) | ||
| Net loss available to common stockholders, diluted: | (44,764,000) | (49,391,000) | (35,592,000) | (36,291,000) | (31,367,000) | (25,571,000) | ||
Comprehensive Income (USD)Annual | Quarterly
| 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (44,764,000) | (49,391,000) | (35,592,000) | (36,291,000) | (31,367,000) | (25,571,000) | ||
| Comprehensive loss: | (44,764,000) | (49,391,000) | (35,592,000) | (36,291,000) | (31,367,000) | (25,571,000) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 159,000 | 127,000 | (93,000) | (4,000) | 51,000 | (14,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (44,605,000) | (49,264,000) | (35,685,000) | (36,295,000) | (31,316,000) | (25,585,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.